Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R R Bies

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|April 5, 2008
Mathematics for understanding diseaseR R Bies, M R Gastonguay, S L Schwartz
Clinical Pharmacology and Therapeutics|September 19, 2009
Predicting age-specific dosing of antipsychoticsH Uchida, B G Pollock, R R Bies, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 10, 2013
Growth of screen-detected abdominal aortic aneurysms in men: a bayesian analysisE A Sherer, R R Bies, P Clancy, et al.
Molecular Psychiatry|April 27, 2011
Genetic variation in CYP3A43 explains racial difference in olanzapine clearanceK L Bigos, R R Bies, B G Pollock, et al.
Journal of Clinical Pharmacy and Therapeutics|May 18, 2005
Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safetyS L Kane-Gill, Y Feng, M B Bobek, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 27, 2013
Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancerK Wu, E E W Cohen, L K House, et al.
Clinical Pharmacology and Therapeutics|February 28, 2013
Estimation of renal cell carcinoma treatment effects from disease progression modelingM L Maitland, K Wu, M R Sharma, et al.
Pharmacopsychiatry|October 28, 2015
Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic StudyT Tsuboi, R R Bies, T Suzuki, et al.
Clinical and Translational Science|January 22, 2016
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics ModelingC H Li, R R Bies, Y Wang, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|April 5, 2008
Mathematics for understanding diseaseR R Bies, M R Gastonguay, S L Schwartz
Clinical Pharmacology and Therapeutics|September 19, 2009
Predicting age-specific dosing of antipsychoticsH Uchida, B G Pollock, R R Bies, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 10, 2013
Growth of screen-detected abdominal aortic aneurysms in men: a bayesian analysisE A Sherer, R R Bies, P Clancy, et al.
Molecular Psychiatry|April 27, 2011
Genetic variation in CYP3A43 explains racial difference in olanzapine clearanceK L Bigos, R R Bies, B G Pollock, et al.
Journal of Clinical Pharmacy and Therapeutics|May 18, 2005
Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safetyS L Kane-Gill, Y Feng, M B Bobek, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 27, 2013
Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancerK Wu, E E W Cohen, L K House, et al.
Clinical Pharmacology and Therapeutics|February 28, 2013
Estimation of renal cell carcinoma treatment effects from disease progression modelingM L Maitland, K Wu, M R Sharma, et al.
Pharmacopsychiatry|October 28, 2015
Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic StudyT Tsuboi, R R Bies, T Suzuki, et al.
Clinical and Translational Science|January 22, 2016
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics ModelingC H Li, R R Bies, Y Wang, et al.
Pageof 1